As RDD 2026 is about to get underway in Phoenix, AZ, USA, some of the meeting sponsors and exhibitors are previewing their conference activities. As always, RDD is sponsored by dozens of organizations that offer products and services for development and manufacturing of OINDPs. The 2026 tabletop technology exhibition will feature approximately 60 companies that will provide information to delegates, and many of the sponsors will also present workshops, papers, and posters.
Exhibitors range in size from small consulting firms to multinational CDMOs and represent a wide range of activities, including inhaled and nasal drug delivery devices; contract analysis and development; and manufacturing and testing equipment.
As has been the case in recent years, manufacturers of LGWP propellants Solstice Advanced Materials and Orbia will be among the exhibitors, as well as companies offering service for the LGWP MDI propellant transition for MDIs. In addition to its tabletop exhibit, Solstice will present 5 posters related to its HFO‑1234ze(E) propellant and will present a workshop titled “Building Regulatory Confidence in LGWP Propellant, HFO‑1234ze(E), Through Science and Collaboration.”
Solstice Medical Propellant General Manager Andrew Van Deusen commented, “RDD is a critical forum for advancing collaboration across the inhalation ecosystem. Our presence at RDD 2026 reflects Solstice’s commitment to working closely with partners to support the transition to next‑generation inhalation propellants.”
Sponsors Bespak and Proveris Scientific will both present workshops related to the LGWP transition in addition to participating in the exhibition. Aptar Pharma and its subsidiary Nanopharm will both exhibit, and Nanopharm’s Lucas Silva will present a podium talk on “Evaluating pMDI Performance in the Propellant Transition Era: Formulation, Device and Analytical insights.”
Other areas highlighted by sponsors include inhaled biologics and innovations in dry powder formulations, including nasal powders. In addition to its tabletop exhibit, Aptar Pharma will present a workshop titled, “From Bench to Biologic: A Hands-On Journey to Creating a Dry Powder Inhaler or Nebulizer Product.” Intertek, which has been increasing its offerings for testing of inhaled biologics will exhibit, and the company’s Senior Scientific Director Mark Parry will present a talk on “Building analytical best practices for respiratory biologics – raiding the biological and respiratory toolboxes.”
Copley Scientific, which debuted its new lung dissolution testing apparatus at DDL 2025, will present a workshop on “Advancing Inhaled Dissolution Testing for Inhaled Drug Products” in addition to exhibiting in the Inspiring Dry Powder Inhalation knowledge space. Other companies focusing on realistic testing of OINDPs include Proveris Scientific, which says that it “will be demonstrating how controlled actuation, human-realistic models, and physiologically relevant breathing profiles can be combined to better understand how products perform under real conditions.”
Delegates who want to contact exhibitors ahead of time can already log into their accounts on the RDD 2026 site and use the conference messaging feature.
Exhibitors at RDD 2026 include:
